SG11201903411YA - Anti-p53 antibodies - Google Patents

Anti-p53 antibodies

Info

Publication number
SG11201903411YA
SG11201903411YA SG11201903411YA SG11201903411YA SG11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA SG 11201903411Y A SG11201903411Y A SG 11201903411YA
Authority
SG
Singapore
Prior art keywords
singapore
international
polypeptide
agency
antibodies
Prior art date
Application number
SG11201903411YA
Other languages
English (en)
Inventor
Tr Kanaga Sabapathy
David P Lane
Le-Ann Hwang
Xin Yu Koh
Liew Oi Wah
Original Assignee
Agency Science Tech & Res
Singapore Health Serv Pte Ltd
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Singapore Health Serv Pte Ltd, Nat Univ Singapore filed Critical Agency Science Tech & Res
Publication of SG11201903411YA publication Critical patent/SG11201903411YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201903411YA 2016-10-17 2017-10-17 Anti-p53 antibodies SG11201903411YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1617564.8A GB201617564D0 (en) 2016-10-17 2016-10-17 Anti-p53 antibodies
PCT/SG2017/050522 WO2018074978A1 (en) 2016-10-17 2017-10-17 Anti-p53 antibodies

Publications (1)

Publication Number Publication Date
SG11201903411YA true SG11201903411YA (en) 2019-05-30

Family

ID=57680660

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903411YA SG11201903411YA (en) 2016-10-17 2017-10-17 Anti-p53 antibodies

Country Status (7)

Country Link
US (3) US11613568B2 (https=)
EP (1) EP3526251A4 (https=)
JP (1) JP7173964B2 (https=)
CN (1) CN110770252A (https=)
GB (1) GB201617564D0 (https=)
SG (1) SG11201903411YA (https=)
WO (1) WO2018074978A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503036A (ja) * 2016-12-27 2020-01-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド ペットフード組成物
EP4077370A4 (en) * 2019-12-17 2024-02-28 The Johns Hopkins University MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE
GB202008688D0 (en) 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
CN113403286B (zh) * 2021-06-24 2024-01-16 新乡学院 一种靶向性三展示噬菌体及其制备方法和应用
EP4412650A1 (en) * 2021-10-05 2024-08-14 The Penn State Research Foundation Methods for treating cancers with mutated p53
CN116178501B (zh) * 2021-11-29 2025-08-29 深圳碳云智肽药物科技有限公司 靶向p53的多肽及其在制备用于治疗癌症的药物中的应用
EP4448583A4 (en) * 2021-12-16 2025-12-17 Univ Johns Hopkins MANABODIES AGAINST P53 TUMORANTIGENS AND METHOD FOR USE
TW202340474A (zh) * 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
CN114574524A (zh) * 2022-03-14 2022-06-03 深圳市体内生物医药科技有限公司 一种从全基因组中筛选肝癌抑癌基因的方法及其应用
WO2024178128A1 (en) * 2023-02-22 2024-08-29 Elysion Therapeutics, Inc. Lysis sensing receptors and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025259636A1 (en) * 2024-06-10 2025-12-18 Baylor College Of Medicine Targeting p53 mutants

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083709A (en) 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
ES2264239T3 (es) 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
EP0576476B1 (en) * 1991-02-01 2003-05-28 OSI Pharmaceuticals, Inc. Immunoassay for detection of mutant p53 polypeptide in biological fluids
US5646016A (en) 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
US20030086935A1 (en) 1992-07-22 2003-05-08 Levine Arnold J. p53 vaccine
JPH07509251A (ja) * 1992-07-22 1995-10-12 ザ トラスティーズ オブ プリンストン ユニバーシティ ｐ５３ワクチン
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
US6630584B1 (en) 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
EP1863846B1 (en) * 2005-03-25 2009-07-22 Ramot at Tel-Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
WO2009112075A1 (en) * 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8728479B2 (en) * 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
WO2013036208A1 (en) 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides

Also Published As

Publication number Publication date
EP3526251A1 (en) 2019-08-21
US12195526B2 (en) 2025-01-14
US20190248879A1 (en) 2019-08-15
US11613568B2 (en) 2023-03-28
WO2018074978A1 (en) 2018-04-26
US20230257457A1 (en) 2023-08-17
GB201617564D0 (en) 2016-11-30
JP7173964B2 (ja) 2022-11-16
US20250263475A1 (en) 2025-08-21
EP3526251A4 (en) 2020-06-10
CN110770252A (zh) 2020-02-07
JP2019535241A (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
SG11201903411YA (en) Anti-p53 antibodies
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201805835WA (en) Modified oncolytic virus
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201807912SA (en) Vaccine against rsv
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201901611YA (en) Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof
SG11201806392XA (en) Personalized delivery vector-based immunotherapy and uses thereof
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201909466RA (en) Human anti-semaphorin 4d antibody
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201810471YA (en) T cell expansion
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201907207UA (en) Pharmaceutical combinations comprising an anti-ly75 antibody